来自MSN6 小时
Medigene and EpimAb to develop T cell engagers for solid tumours
Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell ...
Bambusa Therapeutics doses first volunteers in Phase I bispecific AD trial
The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...
"There’s No Cure Without Us”: One Woman’s Mission To Transform Awareness And Care For ...
After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...
CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or ...
Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple ...
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Goldman starts Summit Therapeutics with a Buy on ivonescimab potential
Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...